Table 4.

Summary results for sensitivity analyses of pooled adjusted hazard ratios (95% confidence intervals) for major adverse cardiovascular events (MACE) and heart failure associated with use of sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP-4) inhibitors

Sensitivity analyses	Adjusted hazard ratio (95% CI)*	I2 (%)
MACE
Main analysis	0.76 (0.69 to 0.84)	47
Intention-to-treat approach	0.80 (0.73 to 0.88)	45
Grace period (days):
0	0.75 (0.67 to 0.85)	0
60	0.75 (0.69 to 0.81)	34
New user status:
Incident users	0.81 (0.71 to 0.93)	44
Prevalent users	0.71 (0.65 to 0.76)	0
Prevalent users:
Adding a SGLT2 inhibitor	0.72 (0.63 to 0.82)	0
Switching to a SGLT2 inhibitor	0.70 (0.64 to 0.77)	0
Heart failure
Main analysis	0.43 (0.37 to 0.51)	43
Intention-to-treat approach	0.52 (0.45 to 0.61)	43
Grace period (days):
0	0.47 (0.32 to 0.69)	48
60	0.43 (0.35 to 0.53)	68
New user status:
Incident users	0.46 (0.38 to 0.56)	26
Prevalent users	0.41 (0.30 to 0.55)	55
Prevalent users:
Adding a SGLT2 inhibitor	0.40 (0.31 to 0.51)	0
Switching to a SGLT2 inhibitor	0.39 (0.27 to 0.56)	62

Nova Scotia had zero events in one of the treatment groups and thus was not included in the following analyses for MACE: grace period (0 days), new user status (prevalent users), and prevalent users. Nova Scotia, Alberta, Saskatchewan, and the Clinical Practice Research Datalink had zero events in one of the treatment groups in the prevalent user analysis involving the addition of a SGLT2 inhibitor and were thus excluded from this analysis.

^*Adjusted for age (continuous), sex, diabetes duration (continuous), and 10ths of time conditional propensity score.